Abstract
Mycobacterial infections (particularly, tuberculosis caused by Mycobacterium tuberculosis) represent a significant threat to public health, especially south of the Sahara. The problem has been compounded by poor patient compliance due to long periods of treatment, thus resulting in the development of multi-drug resistant (MDR) and extremely drugresistant (XDR) forms the of bacterium. It has, therefore, become imperative to seek new drugs from unexplored sources against these infections. Natural products, from ancient times, have often been used as drugs for the treatment of various ailments. They have also served as templates for the design and synthesis of new drugs. In sub-Saharan Africa particularly, ethnobotanical and ethnomedical knowledge of plants has been exploited to manage several different ailments, including tuberculosis. Thus research efforts have often been concentrated on plants as a source of treatment of diseases as well as drug leads. In this mini review, we report the biological activities of compounds derived from African medicinal plants with the potential for the treatment of anti-mycobacterial infections. Seventy nine (79) antimycobacterial compounds have been identified in sub-Sahara Africa covering the period from 1995 to 2013.
Keywords: Drug discovery, medicinal plants, mycobacterial infections, natural products, tuberculosis.
Anti-Infective Agents
Title:Potential Natural Antimycobacterial Metabolites from Some Sub-Saharan Medicinal Plants
Volume: 12 Issue: 2
Author(s): Joseph N. Yong and Fidele Ntie-Kang
Affiliation:
Keywords: Drug discovery, medicinal plants, mycobacterial infections, natural products, tuberculosis.
Abstract: Mycobacterial infections (particularly, tuberculosis caused by Mycobacterium tuberculosis) represent a significant threat to public health, especially south of the Sahara. The problem has been compounded by poor patient compliance due to long periods of treatment, thus resulting in the development of multi-drug resistant (MDR) and extremely drugresistant (XDR) forms the of bacterium. It has, therefore, become imperative to seek new drugs from unexplored sources against these infections. Natural products, from ancient times, have often been used as drugs for the treatment of various ailments. They have also served as templates for the design and synthesis of new drugs. In sub-Saharan Africa particularly, ethnobotanical and ethnomedical knowledge of plants has been exploited to manage several different ailments, including tuberculosis. Thus research efforts have often been concentrated on plants as a source of treatment of diseases as well as drug leads. In this mini review, we report the biological activities of compounds derived from African medicinal plants with the potential for the treatment of anti-mycobacterial infections. Seventy nine (79) antimycobacterial compounds have been identified in sub-Sahara Africa covering the period from 1995 to 2013.
Export Options
About this article
Cite this article as:
Yong N. Joseph and Ntie-Kang Fidele, Potential Natural Antimycobacterial Metabolites from Some Sub-Saharan Medicinal Plants, Anti-Infective Agents 2014; 12 (2) . https://dx.doi.org/10.2174/2211352512666140417002335
DOI https://dx.doi.org/10.2174/2211352512666140417002335 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Screening and Docking Analysis of Hispolon Pyrazoles and Isoxazoles as Potential Antitubercular Agents
Current Topics in Medicinal Chemistry Targeting Cytokines: Production and Characterization of Anti-TNF-α scFvs by Phage Display Technology
Current Pharmaceutical Design Structure Based Design of CYP51 Inhibitors
Current Topics in Medicinal Chemistry Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Infectious Disorders - Drug Targets Tuberculous Pericarditis
Current Cardiology Reviews NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity
Current Topics in Medicinal Chemistry Pulmonary Tuberculosis in Various Gene Knockout Mice With Special Emphasis on Roles of Cytokines and Transcription Factors
Current Respiratory Medicine Reviews Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling
Combinatorial Chemistry & High Throughput Screening PET Imaging for Gene & Cell Therapy
Current Gene Therapy Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Personalized and Predictive Medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009
Current Pharmacogenomics and Personalized Medicine Affordable Antiretroviral Drugs for the Under-Served Markets: How to Expand Equitable Access Against the Backdrop of Challenging Scenarios?
Current HIV Research Tuberculosis and its Treatment: An Overview
Mini-Reviews in Medicinal Chemistry PeMtb: A Database of MHC Antigenic Peptide of Mycobacterium tuberculosis
Current Pharmaceutical Biotechnology 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Current Drug Delivery Anti-Tuberculosis
Current Bioactive Compounds New insights on Ethambutol Targets in Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Archaeosome Immunostimulatory Vaccine Delivery System
Current Drug Delivery Social Determinants Associated with Tuberculosis Mortality in a General Hospital in Mexico
Current Respiratory Medicine Reviews Synthesis of 99mTc-Rifabutin: A Potential Tuberculosis Radiodiagnostic Agent
Infectious Disorders - Drug Targets